{
    "info": {
        "nct_id": "NCT02923921",
        "official_title": "Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen",
        "inclusion_criteria": "1. The presence of metastatic pancreatic adenocarcinoma\n2. Measurable disease per RECIST v.1.1\n3. Participant must have documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease as established by CT or MRI scan\n4. Eastern Cooperative Oncology Group Performance Status of 0 - 1\n5. Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to randomization and recovered from toxicity to Grade 1 or baseline\n6. Participants must not have received previous radiation therapy or investigational therapy for the treatment of advanced metastatic disease.\n7. Participants having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study\n8. No peripheral neuropathy\n9. No known history of dihydropyrimidine dehydrogenase deficiency\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinoma\n2. Participant on Coumadin and not willing to change to LMWH or oral Factor II or Xa inhibitor with half-life of less than 24 hours.\n3. Participant has received prior treatment with pegilodecakin or fluoropyrimidine/platinum containing regimen\n4. Participants who were intolerant of a gemcitabine containing regimen.\n5. History of positivity for human immunodeficiency virus\n6. Chronic active or active viral hepatitis A, B, or C infection\n7. Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)\n8. Pregnant or lactating women\n9. Participants with a history of immune-mediated neurological disorders such as multiple sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders\n10. Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks\n11. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy),within 28 days prior to randomization or anticipated surgery during the study period\n12. Prior history of receiving immune modulators including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "4. Eastern Cooperative Oncology Group Performance Status of 0 - 1",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group Performance Status of 0 - 1",
                        "criterion": "Eastern Cooperative Oncology Group (ECOG) Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group Performance Status of 0 - 1",
                        "criterion": "Eastern Cooperative Oncology Group (ECOG) Performance Status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. No peripheral neuropathy",
                "criterions": [
                    {
                        "exact_snippets": "No peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No peripheral neuropathy",
                        "criterion": "peripheral neuropathy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Participants must not have received previous radiation therapy or investigational therapy for the treatment of advanced metastatic disease.",
                "criterions": [
                    {
                        "exact_snippets": "must not have received previous radiation therapy ... for the treatment of advanced metastatic disease",
                        "criterion": "previous radiation therapy for advanced metastatic disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "must not have received previous ... investigational therapy for the treatment of advanced metastatic disease",
                        "criterion": "previous investigational therapy for advanced metastatic disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "must not have received previous radiation therapy ... for the treatment of advanced metastatic disease",
                        "criterion": "previous radiation therapy for advanced metastatic disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "must not have received previous ... investigational therapy for the treatment of advanced metastatic disease",
                        "criterion": "previous investigational therapy for advanced metastatic disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Participants having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study",
                "criterions": [
                    {
                        "exact_snippets": "Participants having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible",
                        "criterion": "prior cytotoxic chemotherapy in the adjuvant setting",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Participants having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible",
                        "criterion": "prior cytotoxic chemotherapy in the adjuvant setting",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. No known history of dihydropyrimidine dehydrogenase deficiency",
                "criterions": [
                    {
                        "exact_snippets": "No known history of dihydropyrimidine dehydrogenase deficiency",
                        "criterion": "dihydropyrimidine dehydrogenase deficiency",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "No known history of dihydropyrimidine dehydrogenase deficiency",
                        "criterion": "dihydropyrimidine dehydrogenase deficiency",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Measurable disease per RECIST v.1.1",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease per RECIST v.1.1",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease per RECIST v.1.1",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v.1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease per RECIST v.1.1",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease per RECIST v.1.1",
                        "criterion": "disease",
                        "requirement": {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v.1.1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. The presence of metastatic pancreatic adenocarcinoma",
                "criterions": [
                    {
                        "exact_snippets": "The presence of metastatic pancreatic adenocarcinoma",
                        "criterion": "metastatic pancreatic adenocarcinoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "The presence of metastatic pancreatic adenocarcinoma",
                        "criterion": "metastatic pancreatic adenocarcinoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "7. Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)",
                        "criterion": "clinically significant bleeding",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)",
                        "criterion": "clinically significant bleeding",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to randomization"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)",
                            "criterion": "clinically significant bleeding",
                            "requirement": {
                                "requirement_type": "presence",
                                "expected_value": false
                            }
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)",
                        "criterion": "clinically significant bleeding",
                        "requirement": {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to randomization"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinoma",
                "criterions": [
                    {
                        "exact_snippets": "Diagnosis of pancreatic islet neoplasm",
                        "criterion": "pancreatic islet neoplasm",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... acinar cell carcinoma",
                        "criterion": "acinar cell carcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... non- adenocarcinoma (i.e., lymphoma, sarcoma)",
                        "criterion": "non-adenocarcinoma (lymphoma, sarcoma)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... adenocarcinoma originating from the biliary tree",
                        "criterion": "adenocarcinoma originating from the biliary tree",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... cystadenocarcinoma",
                        "criterion": "cystadenocarcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Diagnosis of pancreatic islet neoplasm",
                        "criterion": "pancreatic islet neoplasm",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... acinar cell carcinoma",
                        "criterion": "acinar cell carcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... non- adenocarcinoma (i.e., lymphoma, sarcoma)",
                        "criterion": "non-adenocarcinoma (lymphoma, sarcoma)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... adenocarcinoma originating from the biliary tree",
                        "criterion": "adenocarcinoma originating from the biliary tree",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Diagnosis of ... cystadenocarcinoma",
                        "criterion": "cystadenocarcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Participant has received prior treatment with pegilodecakin or fluoropyrimidine/platinum containing regimen",
                "criterions": [
                    {
                        "exact_snippets": "Participant has received prior treatment with pegilodecakin",
                        "criterion": "prior treatment with pegilodecakin",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participant has received prior treatment with ... fluoropyrimidine/platinum containing regimen",
                        "criterion": "prior treatment with fluoropyrimidine/platinum containing regimen",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Participant has received prior treatment with pegilodecakin",
                        "criterion": "prior treatment with pegilodecakin",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participant has received prior treatment with ... fluoropyrimidine/platinum containing regimen",
                        "criterion": "prior treatment with fluoropyrimidine/platinum containing regimen",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Pregnant or lactating women",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant ... women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating women",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant ... women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "lactating women",
                        "criterion": "lactation status",
                        "requirement": {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. History of positivity for human immunodeficiency virus",
                "criterions": [
                    {
                        "exact_snippets": "History of positivity for human immunodeficiency virus",
                        "criterion": "human immunodeficiency virus (HIV) infection",
                        "requirement": {
                            "requirement_type": "history of positivity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "History of positivity for human immunodeficiency virus",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirement": {
                        "requirement_type": "history of positivity",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Participants who were intolerant of a gemcitabine containing regimen.",
                "criterions": [
                    {
                        "exact_snippets": "Participants who were intolerant of a gemcitabine containing regimen",
                        "criterion": "intolerance to gemcitabine containing regimen",
                        "requirement": {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Participants who were intolerant of a gemcitabine containing regimen",
                    "criterion": "intolerance to gemcitabine containing regimen",
                    "requirement": {
                        "requirement_type": "intolerance",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Prior history of receiving immune modulators including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                "criterions": [
                    {
                        "exact_snippets": "Prior history of receiving immune modulators",
                        "criterion": "immune modulator therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-CTLA4 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-PD1 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-PD-L1 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior history of receiving immune modulators",
                        "criterion": "immune modulator therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-CTLA4 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-PD1 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including, but not limited to, anti-CTLA4, anti-PD1, anti-PD-L1",
                        "criterion": "anti-PD-L1 therapy",
                        "requirement": {
                            "requirement_type": "prior history of receiving",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Chronic active or active viral hepatitis A, B, or C infection",
                "criterions": [
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis A infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    },
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    },
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis A infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    },
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis B infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    },
                    {
                        "exact_snippets": "Chronic active or active viral hepatitis A, B, or C infection",
                        "criterion": "viral hepatitis C infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "chronic active or active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "paracentesis frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "every 2 weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "paracentesis frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "every 2 weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Participants with a history of immune-mediated neurological disorders such as multiple sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders",
                "criterions": [
                    {
                        "exact_snippets": "history of immune-mediated neurological disorders",
                        "criterion": "immune-mediated neurological disorders",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "multiple sclerosis",
                        "criterion": "multiple sclerosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Guillain-Barré",
                        "criterion": "Guillain-Barré syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inflammatory CNS/PNS disorders",
                        "criterion": "inflammatory CNS/PNS disorders",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "history of immune-mediated neurological disorders",
                        "criterion": "immune-mediated neurological disorders",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "multiple sclerosis",
                        "criterion": "multiple sclerosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Guillain-Barré",
                        "criterion": "Guillain-Barré syndrome",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inflammatory CNS/PNS disorders",
                        "criterion": "inflammatory CNS/PNS disorders",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "3. Participant must have documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease as established by CT or MRI scan",
                "criterions": [
                    {
                        "exact_snippets": "documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease",
                        "criterion": "tumor progression",
                        "requirement": {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "documented tumor progression during or following a gemcitabine containing regimen to treat metastatic disease",
                        "criterion": "tumor progression",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "during or following a gemcitabine containing regimen to treat metastatic disease"
                        }
                    },
                    {
                        "exact_snippets": "as established by CT or MRI scan",
                        "criterion": "tumor progression assessment method",
                        "requirement": {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "CT scan",
                                "MRI scan"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "5. Participant must have completed prior chemotherapy at least 2 weeks (washout period) prior to randomization and recovered from toxicity to Grade 1 or baseline",
                "criterions": [
                    {
                        "exact_snippets": "completed prior chemotherapy at least 2 weeks (washout period) prior to randomization",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "completion_time_before_randomization",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "recovered from toxicity to Grade 1 or baseline",
                        "criterion": "toxicity from prior chemotherapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Grade 1",
                                "baseline"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "11. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy),within 28 days prior to randomization or anticipated surgery during the study period",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision ... within 28 days prior to randomization",
                        "criterion": "major surgery within 28 days prior to randomization",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "anticipated surgery during the study period",
                        "criterion": "anticipated surgery during the study period",
                        "requirement": {
                            "requirement_type": "anticipated occurrence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision ... within 28 days prior to randomization",
                        "criterion": "major surgery within 28 days prior to randomization",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "anticipated surgery during the study period",
                        "criterion": "anticipated surgery during the study period",
                        "requirement": {
                            "requirement_type": "anticipated occurrence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Participant on Coumadin and not willing to change to LMWH or oral Factor II or Xa inhibitor with half-life of less than 24 hours.",
                "criterions": [
                    {
                        "exact_snippets": "Participant on Coumadin",
                        "criterion": "current anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "medication",
                            "expected_value": "Coumadin"
                        }
                    },
                    {
                        "exact_snippets": "not willing to change to LMWH or oral Factor II or Xa inhibitor with half-life of less than 24 hours",
                        "criterion": "willingness to change anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "willingness to change",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not willing to change to LMWH or oral Factor II or Xa inhibitor with half-life of less than 24 hours",
                        "criterion": "willingness to change anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "alternative medications",
                            "expected_value": [
                                "LMWH",
                                "oral Factor II inhibitor",
                                "oral Xa inhibitor"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "not willing to change to LMWH or oral Factor II or Xa inhibitor with half-life of less than 24 hours",
                        "criterion": "willingness to change anticoagulant therapy",
                        "requirement": {
                            "requirement_type": "half-life",
                            "expected_value": {
                                "operator": "<",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}